December 9, 2019
As another year comes to an end, it is my pleasure to share with you an update on our progress and information on some exciting new initiatives underway in the MGH Immunobiology Lab. We are thrilled that the 150 patient Phase II clinical trial is fully funded, completely enrolled and on track to be finished in the next three and a half years. In 2020, we hope to launch two new clinical trials: our Expanded Access program and a pediatric trial. The steps to initiate these studies are underway along with our efforts to raise the necessary funds.
Also, we just returned from the 4th International BCG and Autoimmunity Conference in Barcelona, which we organize every two years to bring together the global coalition of researchers testing BCG for autoimmune diseases as well as the scientists who are trying to unravel how this incredible vaccine safely impacts the immune system. Good news about BCG is coming from all corners of the globe! Our discussions have evolved to explore how an affordable vaccine like BCG, as an alternative to expensive devices and interventions, could have an impact in reducing the burden of rising health costs.
Attached please find a brochure that describes our progress in greater detail. We have a lot of work to do before we can bring BCG to market with an FDA approved indication for type I diabetes. Anything you can do to help us meet our fundraising goals and turn our full attention back to the research is appreciated.
Thank you so much for your support!
With Kind regards,
Denise L. Faustman, MD, PhD